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The elucidation of virus-cancer associations is of particular importance since 
large numbers of people are potentially exposed to cancer. The first link 
relates to the causation of adult T-cell leukaemia/lymphoma (ATL), a highly 
malignant haematological malignancy of mature activated T cells with a poor 
prognosis, by a retrovirus called human T-cell lymphotropic virus type-1 
(HTLV-1). The HTLV-1 tax oncoprotein plays an integral role in productive 
viral replication and disease progression. Seroprevalence studies 
demonstrated that the distribution of HTLV-1 is heterogeneous worldwide 
and not specific to a particular region only. Patients with this disease have a 
very poor prognosis because of intrinsic chemoresistance and severe 
immunosuppression. Hence, the general objective of the present study is to 
establish the prevalence of HTLV infections in leukaemia and lymphoma 
adult patients. The experimental design consists of two folds: screening for 
the presence of HTLV-1 tax gene and chemosensitivity profiles of patient 
cells treated with clinical chemotherapeutic agents. A total of 140 subjects 
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consisted of lymphoid leukaemia (12%), myeloid leukaemia (26%) and 
lymphoma patients (62%) were included in this study. First line screening 
was performed using ELISA and PCR was used to detect HTLV-1 tax gene 
followed by confirmation using direct DNA sequencing. Mononuclear cells 
were isolated using density gradient centrifugation from bone marrow or 
peripheral blood samples of adult patients admitted to Universiti Malaya 
Medical Centre (UMMC), Ward 6TD. Patient cells were treated based on 
standard chemotherapeutic regimen for 96 hours and assessed using 3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) cytotoxicity 
assay. Initial ELISA screening showed 9 samples were initially reactive and 7 
patients were classified indeterminate due to inconsistency of immunoassay 
replicates. Further confirmation by PCR validated all seropositive patients 
and only four of the indeterminate samples, which yields a prevalence of 
9.29% in 140 adult patients. Concurrently, the HTLV-1 tax positive patient’s 
chemosensitivity profiles were compared with the seronegative samples. 
However, a distinct relationship between the presence of HTLV-1 tax gene 
and chemosensitivity between these groups were not obtained. This 
preliminary study provided a baseline data on the prevalence of HTLV-1 
infections in leukaemia and lymphoma adult patients. However, the lack of 
direct association of HTLV-1 tax gene with the chemotherapy resistance was 
mainly due to the limited sample size used in this study. Further studies 
should be performed in a larger cohort of patients and healthy subjects to 
further substantiate the preliminary data. 
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Penakrifan dalam hubungan virus-kanser adalah sangat penting 
memandangkan semakin ramai yang terdedah kepadanya. Bukti pertama 
dapat dikesan melalui kewujudan sel T leukemia/lymphoma (ATL), iaitu suatu 
keadaan kanser yang malignan dalam hematologi, hasilnya dari sel T 
matang, yang telah diaktifkan dengan prognosis yang lemah oleh retrovirus 
yang dikenali sebagai Human T-cell lymphotropic virus type-1 (HTLV-1).  
HTLV-1 tax onkoprotein memainkan peranan secara integrasi dalam replikasi 
virus secara produktif dan pengaktifan penyakit. Kajian seroprevalens 
menunjukkan bahawa taburan HTLV-1 adalah secara heterogeneous di 
seluruh dunia dan bukannya khusus kepada sesuatu kawasan sahaja. Para 
pesakit menunjukkan penampilan fizikal yang kurang daya tenaga akibat 
kesan dalaman terhadap rintangan kemo serta hilang daya tahan penyakit 
yang serius. Berdasarkan hakikat ini, objektif umum kajian ini ialah untuk 
menetapkan prevalens jangkitan HTLV untuk pesakit-pesakit leukemia dan 
limfoma dewasa. Rekabentuk kajian terdri daripada dua bahagian: 
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penyaringan gen tax HTLV-1 dan profil kemosensitiviti sel pesakit selepas 
dirawat menggunakan agen-agen kemoterapeutik. Sejumlah 140 sampel 
merangkumi limfoid leukaemia (12%), myeloid leukaemia (26%) dan juga 
kes-kes limfoma (62%) telah diambil kira. Penyaringan dasar adalah 
menggunakan ELISA dan PCR digunakan untuk mengesan gen tax HTLV-1 
serta diikuti oleh DNA sekuensing sebagai kaedah pengesanan. Sel-sel 
mononuklear daripada sampel darah dan sum-sum tulang pesakit dewasa 
yang menerima rawatan di Hospital Universiti Malaya (UMMC), Wad 6TD 
diasingkan melalui centrifugasi kecerunan tumpat. Sel-sel pesakit dirawat 
melalui regimen umum untuk 96 jam meggunakan kaedah 3-(4, 5-
dimetiltiazol-2)-2, 5-difeniltetrazolium bromida (MTT) sitotoksik. Penyaringan 
dasar menggunakan teknik ELISA menunjukkan 9 sampel adalah reaktif dan 
7 sampel dikategorikan sebagai ketidakpastian kerana ulangan kaedah yang 
tidak konsisten. PCR menunjukkan semua seropositif pesakit dan hanya 
empat daripada sampel-sampel yang tidak tentu adalah positif untuk HTLV-1 
dengan prevalens 9.29% dalam 140 pesakit dewasa. Dalam pada itu, profil 
kemosensitiviti pesakit-pesakit HTLV-1 positf diasas dengan sample-sampel 
seronegatif. Hakikatnya, tida suatu hubungkait yang kukuh di antara dua 
kumpulan pesakit. Kajian awal ini telah menunjukkan data dasar mengenai 
prevalens jangkitan HTLV-1 di kalangan pesakit-pesakit leukemia dan 
limfoma dewasa. Hubungkaitan yang kukuh dengan gen tax HTLV-1 dan 
kesan kemoterapeutik adalah kurang jelas kerana saiz sampel yang sangat 
kecil.  Kajian lanjut perlu dijalankan di dalam kohort sampel yang lebih besar 
dari golongan pesakit serta subjek-subjek sihat untuk menegaskan data awal 
dari kajian ini. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 Background 
Since the dawn of time, transformation of normal cells of an animal into 
cancer cells is a process which can be induced experimentally by a variety of 
agents. A perplexing aspect of these experiments is the difficulty or 
impossibility, of formulating a unitary mechanism for the various agents. For 
instance, cancer can be induced equally well by substances which have a 
strong action on the nucleic acids, or by hormones, or even by completely 
inert substances, such as sheets of plastic inserted under the skin. The lack 
of similarity in the properties of cancer-inducing agents has suggested that 
the similarity lies in the cellular mechanisms that they affect. 
 
In the past 25 years, revelations on the genesis of human cancer have come 
at an increasing pace. The contributions of knowledge about oncogenic 
infectious agents, especially viruses, have been instrumental in that 
understanding because in transforming cells they mirror, often brilliantly, 
basic cellular processes that culminate in cancer. Infectious agents, chiefly 
viruses, are accepted causes or candidates as causes of diverse 
malignancies of people worldwide. From a universal perspective infectious 
agents especially viruses account for several of the most common 
malignancies – up to 20% of all cancers (Pagano et al., 2004). Some of these 
cancers are endemic with high incidence in certain geographic locations, but 
have sporadic low incidence in other parts of the world. The consistency of 
association of a given virus and a specific malignancy ranges from 
 18
essentially 100% to as low as 15% depending on the virus, the cancer and 
the geographic location. 
 
The elucidation of virus-cancer associations is of particular importance since 
large numbers of people are potentially exposed. The possible role of viruses 
in leukaemogenesis has recently drawn considerable attention, and some 
links between viruses and leukaemia appear to exist. The first link relates to 
the causation of adult T-cell leukaemia/lymphoma (ATL), a highly malignant 
haematological tumour with a poor prognosis, by a retrovirus called human T-
cell lymphotropic virus type-1 (HTLV-1). This virus is endemic in Southern 
Japan, the Caribbean and parts of Central Africa with prevalence in the 
general population of up to 30% and more (Tajima & Cartier, 1995). The 
lifetime risk of ATL among infected persons has been estimated to be 3.0% 
for women and 6.9% for men, with a long latency period of 30 years or more 
(Kondo et al., 1989). An infection in early period of life is particularly 
dangerous, and preventive measures in endemic areas should focus on 
maternal-infant transmission dynamics. In certain geographic areas, about 
60%–80% of ATL are being attributed to this retrovirus (Manns et al., 1993), 
which is not only transmitted via breastfeeding, but also through other routes. 
Among intravenous drug users, HTLV-seropositivity is a common finding 
(Briggs et al., 1995). 
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1.2 Research Significance 
 
This research was set to be an initial step on the prevalence study of HTLV 
infections in this part of the region. 
 
It was a preliminary study of these viruses that could later form a basis for 
further comprehensive research in the development of routine clinical 
diagnostics and treatment protocols for HTLV infections. 
 
 
1.3 Objectives 
 
1.3.1 General Objective 
 
To establish the prevalence of HTLV infections in leukaemia and lymphoma 
patients. 
 
 
1.3.2 Specific Objectives 
 
1. To investigate the presence of HTLV in adult patients diagnosed with 
leukaemia or lymphoma. 
 
2. To identify and characterise HTLV based on serology and genomic 
techniques. 
 
3. To evaluate in vitro chemosensitivity profiles of HTLV-infected as well as 
non-infected leukaemia or lymphoma cells to standard chemotherapeutic 
drugs. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1 Introduction 
 
Human T-cell lymphotropic virus type 1 (HTLV-1), which is also known as 
Human T-cell leukaemia virus, belongs to the genus deltaretrovirus, which 
includes HTLV-2, bovine leukaemia virus (BLV) and simian T-leukaemia virus 
(STLV). As well as HTLV-1, the latter two viruses cause lymphoid 
malignancies in the host. Since STLV and HTLV share the same molecular, 
virological, and epidemiological features, they are designated as primate T-
cell leukaemia viruses (PTLVs).  
 
HTLV-1 is closely related to STLV-1, a virus isolated from old world monkeys 
in Africa. Phylogenic analysis indicates that HTLV-1 originated in Africa, and 
it seems that interspecies transmission from nonhuman primates to man also 
occurred in Africa and disseminated to other locations by the migration of 
Africans to other continents around 27300 ± 8200 years ago (Van Dooren et 
al., 2001). Nevertheless, it does not explain HTLV-1 isolation from Ainu 
indigenous people in Japan and aborigines in Melanesia and Australia.  
 
HTLV-1 subtypes include subtype A, also known as the cosmopolitan 
subtype, which includes the prototype HTLV-1 sequence from Japan (Seiki et 
al., 1982) and is found in many HTLV-1-endemic areas worldwide, subtypes 
B, D, and F from Central Africa, subtype E from South and Central Africa 
(Slattery et al., 1999) and subtype C from Melanesia (Gessain et al., 1991; 
Sherman et al., 1992). HTLV-1 sequences may also be compared to STLV-1 
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isolates from non-human primate species (Vandamme et al., 1994). For most 
HTLV-1 subtypes, STLV-1 isolates from the same geographic region cluster 
closely with the human HTLV-1, suggesting multiple episodes of simian to 
human transmission and a probable African origin of HTLV-1 (Koralnik et al., 
1994; Vandamme et al., 1994). Close sequence similarity between HTLV-1c 
and STLV-1 isolated from Macaca arctoides in Melanesia is an example of 
this phenomenon (Mahieux et al., 1997). 
 
 
2.2 Discovery of HTLV 
 
HTLV-1 was first identified in T-cell lymphoblastoid cell lines and fresh 
peripheral blood lymphocytes obtained from a patient with cutaneous T-cell 
lymphoma (mycosis fungoides) (Poiesz et al., 1980). This virus was 
associated with adult T-cell leukaemia/lymphoma (ATL) (Uchiyama et al., 
1977) because it was observed that the cell line established from peripheral 
blood lymphocytes of a patient with ATL, produced antigens that reacted 
against sera from ATL patients (Hinuma et al., 1981). It was also associated 
with HTLV-1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) 
due to the prevalence of the antibody against this virus in the serum from 
TSP patients (Gessain et al., 1985) and, in the serum and cerebrospinal fluid 
from HAM patients (Osame et al., 1986).  
 
Conversely, HTLV-2 was first identified in a cell line established from the 
spleen of a patient with hairy-cell leukaemia (Kalyanaraman et al., 1982). 
This virus has not yet been associated with any specific disease, although 
some HTLV-2 infected patients have been reported to be affected by atypical 
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T-cell hairy-cell leukaemia of large granular lymphocyte leukaemia 
(Rosenblatt et al., 1986), and tropical ataxic neuropathy (Sheremata et al., 
1993). 
 
 
2.3 Genomic Structure 
 
HTLV-1 virions are complex type C particles, spherical, enveloped and 100–
110 nm in diameter. The viral genome consists of a linear, positive sense, 
ssRNA held together by hydrogen bonds. Each monomer has about 9032 
nucleotides. The 3’ terminal viral genome is polyadenylated and its 5’-
terminal is capped. Each unit is associated with a specific molecule of tRNA 
that is based paired to a region, primer binding site, near the 5’ end of the 
RNA. Proviral forms are flanked at both termini by long terminal repeats 
(LTRs) of 754 nucleotides.  
 
The genomic structure encodes structural and enzymatic proteins: gag, pol, 
env, reverse transcriptase, protease, and integrase (Franchini, 1995). In 
addition, HTLV-1 has a region at the 3’ end of the virus, called pX, which 
encodes four partially overlapping reading frames (ORFs) (Figure 1). These 
ORFs code for regulatory proteins which impact the expression and 
replication of the virus. The names, product size and functions of the genes 
of HTLV-1 are summarised in Table 1. 
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Table 1: Products of HTLV-1 genes 
 
5’ LTR Contains regulatory elements essential for viral replication 
gag Group antigen nucleocapsid protein p19 matrix 
   p24 capsid 
   p15 nucleocapsid 
pol Polymerase reverse transcriptase RT transcription of DNA from RNA 
  proteinase  splicing of protein precursors 
  RNaseH  synthesis of RNA 
  integrase  Integration of proviral DNA into host genome 
env Envelope Surface glycoprotein gp46 (SU) 
  Transmembrane gp21 (TM) 
pX ORF I  p12I  
 ORF II  p13II  
   p30II  
 ORF III  p27 Rex Regulatory gene of ‘X’ region 
   p21rexIII  Cytoplasmic protein unknown function 
 ORF IV  p40 Tax Transactivating gene of ‘X’ region 
3’ LTR Contains regulatory elements essential for viral replication 
 
 
The p12I protein, which is encoded by ORF I, is a small hydrophobic protein 
which localizes to the golgi and endoplasmic reticulum (ER) (Ding et al., 
2001; Johnson et al., 2001; Albrecht & Lairmore, 2002). Although not 
necessary for HTLV-1 replication in vitro, p12I was shown to contribute to 
viral infectivity in vivo using a rabbit animal model system (Collins et al., 
1999; Lairmore et al., 2000; Albrecht et al., 2002). Later studies have linked 
p12I to T cell activation. p12I has been shown to increase signal transducers 
and activators of the STAT5 pathway, increasing DNA binding and 
transcriptional activity in T cell lines as well as primary T cells (Nicot et al., 
2001). In agreement with having a role in T cell activation/proliferation, p12I 
also interacts with both calnexin and calreticulin, ER--resident proteins which 
regulate calcium storage and increase calcium release (Ding et al., 2001). 
 
The ORF II region of the viral mRNA encodes the p30 and p13 accessory 
proteins. When the p30 protein is expressed ectopically, it is found to localise 
to the nucleus and nucleus of transfected cells (Koralnik et al., 1993). The 
p13 represents the C-terminal 87 amino acids of p30. Ectopic expression of 
p13 localises it to the nucleus and mitochondria. While little is known about 
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